Mapping genetic interactions to improve cancer treatment
Expanding the cancer paralog genetic interaction map to enable precision oncology
This study is looking for new ways to improve cancer treatment for people with non-small cell lung cancer by finding specific genes that could help overcome the challenges of drug resistance, aiming to create more personalized and effective treatment options for patients who need them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11039934 on NIH RePORTER |
What this research studies
This research aims to enhance cancer treatment by identifying new genetic targets that can help overcome drug resistance in non-small cell lung cancer. Using advanced techniques like genome-wide CRISPR knockout screens, the team will explore the functions of gene families, particularly those with redundant roles, to uncover potential new therapies. By focusing on paralogous genes, which make up a significant portion of the human genome, the research seeks to develop innovative approaches to personalize cancer treatment for patients. This could lead to more effective options for those who currently have limited therapeutic choices.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those who have developed resistance to existing treatments.
Not a fit: Patients with cancer types other than non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer therapies, improving survival rates for patients with non-small cell lung cancer.
How similar studies have performed: Other research has shown promise in using CRISPR technology to identify new cancer targets, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Berger, Alice — Fred Hutchinson Cancer Center
- Study coordinator: Berger, Alice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.